Luminex Co. (LMNX) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC trimmed its holdings in Luminex Co. (NASDAQ:LMNX) by 0.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 148,198 shares of the medical instruments supplier’s stock after selling 1,138 shares during the quarter. Great Lakes Advisors LLC’s holdings in Luminex were worth $3,410,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of LMNX. Norges Bank acquired a new stake in Luminex in the 4th quarter valued at about $22,764,000. Bessemer Group Inc. lifted its holdings in Luminex by 63.0% in the 4th quarter. Bessemer Group Inc. now owns 866,888 shares of the medical instruments supplier’s stock valued at $20,034,000 after acquiring an additional 335,037 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Luminex by 4.8% in the 3rd quarter. Vanguard Group Inc. now owns 4,268,240 shares of the medical instruments supplier’s stock valued at $129,370,000 after acquiring an additional 194,226 shares during the last quarter. First Trust Advisors LP acquired a new stake in Luminex in the 4th quarter valued at about $1,940,000. Finally, Bank of Montreal Can lifted its holdings in Luminex by 985.0% in the 1st quarter. Bank of Montreal Can now owns 84,513 shares of the medical instruments supplier’s stock valued at $1,944,000 after acquiring an additional 76,724 shares during the last quarter. 85.74% of the stock is owned by institutional investors.

Shares of LMNX opened at $20.82 on Wednesday. The stock has a market capitalization of $944.52 million, a PE ratio of 43.38, a price-to-earnings-growth ratio of 19.44 and a beta of 0.75. Luminex Co. has a fifty-two week low of $20.40 and a fifty-two week high of $35.37. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.70 and a current ratio of 3.99.

Luminex (NASDAQ:LMNX) last issued its earnings results on Monday, May 6th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.14). Luminex had a net margin of 2.55% and a return on equity of 1.62%. The business had revenue of $82.41 million during the quarter, compared to analyst estimates of $83.10 million. During the same quarter in the prior year, the company earned $0.30 EPS. Luminex’s revenue for the quarter was down .3% on a year-over-year basis. On average, sell-side analysts expect that Luminex Co. will post 0.07 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Thursday, June 20th will be issued a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 1.15%. Luminex’s dividend payout ratio (DPR) is presently 50.00%.

A number of analysts have commented on the stock. BidaskClub lowered shares of Luminex from a “hold” rating to a “sell” rating in a research note on Monday. ValuEngine lowered shares of Luminex from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. William Blair reaffirmed a “market perform” rating on shares of Luminex in a research note on Tuesday, May 7th. Finally, Zacks Investment Research lowered shares of Luminex from a “hold” rating to a “sell” rating in a research note on Monday, April 8th. Two analysts have rated the stock with a sell rating and four have given a hold rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $31.33.

TRADEMARK VIOLATION WARNING: “Luminex Co. (LMNX) Shares Sold by Great Lakes Advisors LLC” was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.themarketsdaily.com/2019/05/22/luminex-co-lmnx-shares-sold-by-great-lakes-advisors-llc.html.

Luminex Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

See Also: What is the Stochastic Momentum Index (SMI)?

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.